Comparison of the Effects of Photodynamic Therapy, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1 + PRN Regimen

Overview

Journal BMC Ophthalmol

Publisher Biomed Central

Specialty Ophthalmology

Date 2018 Jun 22

PMID 29925341

Citations 4

Authors

Kunbei Lai

Ying Li

Lijun Zhou

Xiaojin Zhong

Chuangxin Huang

Fabao Xu

Lin Lu

Jian Ge

Chenjin Jin

Affiliations

Soon will be listed here.

Abstract

Background: The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of "1+pro re nata(PRN)" treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1 + PRN" treatment regimen for PCV.

Methods: Fifty-seven eyes of 57 patients completed the 12 months' follow-up in this prospective study. The patients in the PDT arm(n = 23), ranibizumab arm(n = 18), or combination arm(n = 16) underwent a session of PDT, IVR or combination of both at baseline followed by additional IVR as needed. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT) and the regression rate of polyps were evaluated. Cost-benefit analysis was also performed.

Results: At Month 12, the mean logMAR VA improved from 0.90 ± 0.52 to 0.75 ± 0.57 in the PDT group (P < 0.05), from 0.96 ± 0.58 to 0.77 ± 0.41 in the IVR group (P < 0.05), and from 0.94 ± 0.55 to 0.72 ± 0.44 in the combination group (P < 0.05), respectively. The CFT decreased from 478.04 ± 156.70 μm, 527.5 ± 195.90 μm, and 522.63 ± 288.40 μm at the baseline to 366.43 ± 148.28 μm, 373.17 ± 134.88 μm and 328.44 ± 103.25 in the PDT group (P < 0.05), IVR group (P < 0.01), and the combination group (P < 0.05), respectively. However, no statistical difference was found between groups (P > 0.05). PDT treatment (60.87%) was superior to the IVR therapy (22.22%) in achieving complete regression of polyps (P < 0.05). Cost-benefit analysis showed that IVR treatment cost the least money for improving per 0.1logMAR units and the combination therapy demanded the least money for reducing per 100 μm of CFT.

Conclusions: PDT, IVR and the combination therapy have similar efficacy in the VA improvement as well as the reduction of CFT under the "1 + PRN" treatment regimen.

Trial Registration: Current Controlled Trials NCT03459144 . Registered retrospectively on March 2, 2018.

Citing Articles

A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.

Lees J, Dobbin S, Elyan B, Gilmour D, Tomlinson L, Lang N Nephrol Dial Transplant. 2022; 38(7):1666-1681.

PMID: 36318455 PMC: 10310520. DOI: 10.1093/ndt/gfac305.

Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy.

Mao J, Zhang C, Liu C, Zhang Y, Lin J, Xu Z Int J Ophthalmol. 2021; 14(5):719-724.

PMID: 34012887 PMC: 8077010. DOI: 10.18240/ijo.2021.05.12.

Systematic review with network meta-analysis of antivascular endothelial growth factor use in managing polypoidal choroidal vasculopathy.

Chi S, Kang Y, Huang Y Sci Rep. 2021; 11(1):2735.

PMID: 33531615 PMC: 7854625. DOI: 10.1038/s41598-021-82316-y.

The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review.

Wang Y, Shen M, Cheng J, Sun X, Kaiser P J Ophthalmol. 2020; 2020:4924053.

PMID: 32855818 PMC: 7442996. DOI: 10.1155/2020/4924053.

References

Kang H, Koh H . Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013; 156(4):652-60. DOI: 10.1016/j.ajo.2013.05.038. View

Lalwani G, Rosenfeld P, Fung A, Dubovy S, Michels S, Feuer W . A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009; 148(1):43-58.e1. DOI: 10.1016/j.ajo.2009.01.024. View

Stewart M . Individualized Treatment of Neovascular Age-Related Macular Degeneration: What are Patients Gaining? Or Losing?. J Clin Med. 2015; 4(5):1079-101. PMC: 4470218. DOI: 10.3390/jcm4051079. View

. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic.... Arch Ophthalmol. 1999; 117(10):1329-45. View

Nakashizuka H, Mitsumata M, Okisaka S, Shimada H, Kawamura A, Mori R . Clinicopathologic findings in polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci. 2008; 49(11):4729-37. DOI: 10.1167/iovs.08-2134. View

Yuzawa M, Mori R, Kawamura A . The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol. 2005; 89(5):602-7. PMC: 1772616. DOI: 10.1136/bjo.2004.049296. View

Akaza E, Mori R, Yuzawa M . Long-term results of photodynamic therapy of polypoidal choroidal vasculopathy. Retina. 2008; 28(5):717-22. DOI: 10.1097/IAE.0b013e31816577cb. View

Koh A, Lee W, Chen L, Chen S, Hashad Y, Kim H . EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012; 32(8):1453-64. DOI: 10.1097/IAE.0b013e31824f91e8. View

Honda S, Kurimoto Y, Kagotani Y, Yamamoto H, Takagi H, Uenishi M . Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan. Jpn J Ophthalmol. 2009; 53(6):593-597. DOI: 10.1007/s10384-009-0741-0. View

10.

Kokame G . Polypoidal choroidal vasculopathy--an important diagnosis to make with therapeutic implications. Retina. 2012; 32(8):1446-8. DOI: 10.1097/IAE.0b013e3182695bf8. View

11.

Spaide R, Martin M, Slakter J, Yannuzzi L, Sorenson J, Guyer D . Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol. 2002; 134(1):62-8. DOI: 10.1016/s0002-9394(02)01452-6. View

12.

Zhang X, Li M, Wen F, Zuo C, Chen H, Wu K . Different impact of high-density lipoprotein-related genetic variants on polypoidal choroidal vasculopathy and neovascular age-related macular degeneration in a Chinese Han population. Exp Eye Res. 2013; 108:16-22. DOI: 10.1016/j.exer.2012.12.005. View

13.

Rouvas A, Papakostas T, Ntouraki A, Douvali M, Vergados I, Ladas I . Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. Retina. 2010; 31(3):464-74. DOI: 10.1097/IAE.0b013e3181f274ec. View

14.

Koh A, Lai T, Takahashi K, Wong T, Chen L, Ruamviboonsuk P . Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial. JAMA Ophthalmol. 2017; 135(11):1206-1213. PMC: 5710379. DOI: 10.1001/jamaophthalmol.2017.4030. View

15.

Chakravarthy U, Harding S, Rogers C, Downes S, Lotery A, Culliford L . Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet. 2013; 382(9900):1258-67. DOI: 10.1016/S0140-6736(13)61501-9. View

16.

Matsumiya W, Honda S, Kusuhara S, Tsukahara Y, Negi A . Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up. BMC Ophthalmol. 2013; 13:10. PMC: 3627626. DOI: 10.1186/1471-2415-13-10. View

17.

Inoue M, Arakawa A, Yamane S, Kadonosono K . Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy. Eye (Lond). 2013; 27(9):1013-20. PMC: 3772374. DOI: 10.1038/eye.2013.179. View

18.

Nowak-Sliwinska P, van den Bergh H, Sickenberg M, Koh A . Photodynamic therapy for polypoidal choroidal vasculopathy. Prog Retin Eye Res. 2013; 37:182-99. DOI: 10.1016/j.preteyeres.2013.09.003. View

19.

Kang H, Koh H . Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy. Ophthalmologica. 2013; 231(2):86-93. DOI: 10.1159/000354546. View

20.

Mitamura Y, Kitahashi M, Kubota-Taniai M, Yamamoto S . Comparison of intravitreal bevacizumab to photodynamic therapy for polypoidal choroidal vasculopathy: short-term results. Indian J Ophthalmol. 2010; 58(4):291-6. PMC: 2907029. DOI: 10.4103/0301-4738.64130. View